The present disclosure relates to a composition for ameliorating a circulatory system disease, which contains a green tea extract with modified ingredient content. According to the present disclosure, it is possible to effectively prevent, ameliorate and treat circulatory system diseases without side effects and, thereby, to greatly help patients with circulatory system diseases and contribute to the development of related industries.

A beverage product comprising a beverage in a sealed container is provided. The beverage comprises, in water, a combination of buffering components selected from (a) citric acid and trisodium citrate, (b) tartaric acid and disodium tartrate, or (c) malic acid and disodium malate, and glucose and sodium chloride, wherein the beverage has a pH of lower than 4.0. A method and an apparatus suited for producing such a beverage product are also provided.

Oral rehydration solutions (ORSs), methods of preparing ORSs and methods of delivering rehydration therapy are disclosed herein. In some embodiments, an ORS includes a non-starch viscosity enhancing polymer and a sodium salt. The ORS may include at least approximately 50 millimoles of dissolved sodium per liter. Other embodiments may be described and/or claimed.

Oral rehydration solutions (ORSs), methods of preparing ORSs and methods of delivering rehydration therapy are disclosed herein. In some embodiments, an ORS includes a non-starch viscosity enhancing polymer and a sodium salt. The ORS may include at least approximately 50 millimoles of dissolved sodium per liter. Other embodiments may be described and/or claimed.

A shelf stable hydration beverage can be prepared based on a dairy permeate.

A shelf stable hydration beverage can be prepared based on a dairy permeate.

The present invention discloses the microbial anti-adhesion effect of probiotic bacteria Bacillus coagulans MTCC 5856. More specifically the invention discloses the ability of a composition containing probiotic bacteria Bacillus coagulans MTCC 5856 in inhibiting the adhesion of harmful pathogenic microbes to the skin and mucosal surfaces thereby preventing the occurrence of an infection. Compositions containing probiotic bacteria Bacillus coagulans MTCC 5856 along with plant/fruit extracts for use as an anti-adhesion agent are also disclosed.

The present invention discloses the microbial anti-adhesion effect of probiotic bacteria Bacillus coagulans MTCC 5856. More specifically the invention discloses the ability of a composition containing probiotic bacteria Bacillus coagulans MTCC 5856 in inhibiting the adhesion of harmful pathogenic microbes to the skin and mucosal surfaces thereby preventing the occurrence of an infection. Compositions containing probiotic bacteria Bacillus coagulans MTCC 5856 along with plant/fruit extracts for use as an anti-adhesion agent are also disclosed.

The present invention discloses oral isotonic compositions to provide hydration to mammals in need, characterized by no residual chlorine taste, comprising at least three members of a group consisting of steviol glycoside, citric acid monohydrate, glutamic acid, monosodium glutamate and glycine.

The present invention discloses oral isotonic compositions to provide hydration to mammals in need, characterized by no residual chlorine taste, comprising at least three members of a group consisting of steviol glycoside, citric acid monohydrate, glutamic acid, monosodium glutamate and glycine.